Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

PaperCitations, authors & open-access status

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 394 citations, 2016 year and closed oa status.

394
Citations
2016
Year
closed
OA Status

Related on ScholarIQ

Cristian Guja
Author
The Lancet Diabetes & Endocrinology
Journal
Diabetes Treatment and Management
Topic
Diabetes Treatment and Management
Topic
Bariatric Surgery and Outcomes
Topic
Pancreatic function and diabetes
Topic
470M+ articles · free account